Last reviewed · How we verify
Dexamethasone plus Radium-223
Dexamethasone reduces inflammation and immune response while Radium-223 delivers targeted alpha radiation to bone metastases to kill cancer cells.
Dexamethasone reduces inflammation and immune response while Radium-223 delivers targeted alpha radiation to bone metastases to kill cancer cells. Used for Castration-resistant prostate cancer with bone metastases.
At a glance
| Generic name | Dexamethasone plus Radium-223 |
|---|---|
| Also known as | Dexamethasone, Baycadron |
| Sponsor | University Health Network, Toronto |
| Drug class | Combination therapy: corticosteroid plus alpha-emitting radiopharmaceutical |
| Target | Radium-223 targets calcium-mimetic bone uptake; dexamethasone targets glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
Radium-223 is an alpha-emitting radioisotope that localizes to bone and delivers high-energy radiation directly to metastatic lesions, causing DNA damage and cell death in bone-seeking cancers. Dexamethasone, a corticosteroid, is added to reduce inflammation and potentially mitigate radiation-induced inflammatory responses. This combination targets castration-resistant prostate cancer with bone metastases.
Approved indications
- Castration-resistant prostate cancer with bone metastases
Common side effects
- Bone marrow suppression
- Nausea
- Diarrhea
- Immunosuppression (from dexamethasone)
- Fatigue
Key clinical trials
- Radium-223 Combined With Dexamethasone as First-line Therapy in Patients With M+CRPC (PHASE4)
- Study Testing Radium-223 Dichloride in Relapsed Multiple Myeloma (PHASE1, PHASE2)
- A Study of Alpharadin With Docetaxel in Patients With Bone Metastasis From Castration-Resistant Prostate Cancer (CRPC) (PHASE1, PHASE2)
- Phase 1b/2 Study Testing Radium-223 Dichloride/Bortezomib/Dexamethasone Combination in Relapsed Multiple Myeloma (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |